Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

Study ID
NCT02866383

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

CheckPAC

Trial Summary

This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or BTC refractory or intolerant to at least one line of prior systemic chemotherapy with gemcitabine or platinum-containing regimens to determine the efficacy and safety of nivolumab or nivolumab plus ipilimumab administered concurrently with high dose RT. Patients with metastatic PC or BTC who are feasible candidates for radiation and biopsy of primary and/or metastatic lesions will be included.

More informations

Trial Starting Date

Nov 30,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

160